PPARA and primary biliary cholangitis: Over 100 anti-fibrotic therapies have entered clinical trials, with some targeted drugs showing therapeutic potential, including the FXR receptor agonist obeticholic acid for primary biliary cholangitis (PBC) and the PPAR agonist Lanifibranor, both of which have shown significant efficacy in reducing fibrosis in NASH patients [8,9].